Pfizer submits new drug application to FDA for its COVID-19 treatment Paxlovid
Pfizer announced this morning it submitted a new drug application to formally ask the U.S. Food and Drug Administration for full approval of its COVID-19 treatment Paxlovid for patients who are at high risk for progression to severe illness from the virus.
Share:
